Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Article Article scientifique Article Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer eng 2021 author Addeo Alfredo 912644 author Shah Pankil K. author Bordry Natacha 631335 author Hudson Robert D. author Albracht Brenna author Di Marco Mariagrazia 768956 author Kaklamani Virginia author Dietrich Pierre-Yves 96532 author Taylor Barbara S. author Simand Pierre-Francois author Patel Darpan author Wang Jing author Labidi-Galy Sana Intidhar 817058 author Fertani Sara 592936 author Leach Robin J. author Sandoval Jose author Mesa Ruben author Lathrop Kate author Mach Nicolas 0000-0001-8944-1088 32943 author Shah Dimpy P. 1091-1098.e2 10.1016/j.ccell.2021.06.009 34214473 1535-6108 https://linkinghub.elsevier.com/retrieve/pii/S1535610821003305 Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general population; however, few data are available on their efficacy in patients with cancer. Using a prospective cohort, we assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the first and second dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in US and Europe from January to April 2021. Among 131 patients, most (94%) achieved seroconversion after receipt of two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response. Antibody titers were highest for clinical surveillance or endocrine therapy groups and lowest for cytotoxic chemotherapy or monoclonal antibody groups. COVID-19 Anti-cancer treatment Antibody Immune response Malignancy Oncology Pandemic Seroconversion Tumor Vaccine Dewey 616 56 Département de médecine 221 false 388 Immunothérapie 654 27 Immunothérapie des cancers 42 https://github.com/pankil-shah/cancer_cell_covid_vaccine Cancer Cell 39 8 878df2c9-6731-4c5d-9be2-a8d776cf3427 Article (Published version) Public 2021-Cancer-Cell-Immunogenicity-of-SARS-COV2-mRNA-vaccines-in-oncology-patients.pdf 1540376 application/pdf b973bef5-52a7-456c-96a9-33db44575829 Appendix Public mmc1.pdf 2025173 application/pdf Vignette Public 1-s2.0-S1535610821003305-fx1.jpg 55384 image/jpeg openAccess Faculté de médecine / Section de médecine clinique / Département de médecine

Title	Published in	Year	Views	Downloads

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer	Cancer Cell	2021	291	351
Voluminous pseudotumoral mass in a pregnant woman: an extraordinary presentation of retroperitoneal tuberculosis	Infection	2018	219	0
Ipilimumab-related hypophysitis may precede severe CNS immune attack	Annals of Oncology	2016	459	0

Archive ouverte UNIGE

Fertani, Sara